The primary endpoint evaluated pain strength over the 12-hour study period compared to baseline.

The invasive character of IV PCA delivery and the prospect of programming errors when establishing the pump are well-known disadvantages of the method of pain control.. AcelRx Pharmaceuticals reports excellent results in trial of sublingual Sufentanil NanoTabs in treating post-op pain AcelRx Pharmaceuticals, Inc. The primary endpoint evaluated pain strength over the 12-hour study period compared to baseline. Results demonstrated that in comparison to placebo, patients receiving 15 mcg of ARX-01 experienced a statistically significant decrease in pain intensity over the study period, based on the most severe observation carried forwards imputation technique , p=0.015. Additionally, at the 15 mcg dose, the scholarly study met an important secondary endpoint compared to placebo, the %age of patient dropouts due to inadequate analgesia, p=0.006.The usage of anatomical landmarks was more frequent in the subclavian and femoral groupings than in the jugular group. Catheterization was performed more quickly in the femoral group than in either of the other two groups. Alcohol-based items were the predominant cutaneous antiseptics used for cleaning the catheter insertion site; the regularity of the usage of chlorhexidine-containing products was identical among the various insertion sites. The median duration of catheter use was 5 times for every of the three insertion sites . No patients were dropped to follow-up. Catheter-suggestion cultures and peripheral-blood cultures were missing in 101 cases .